ArticleInternational journal of endocrinology2026
Oxidative Phosphorylation in Silent Pituitary Adenomas: A Multiomics Perspective.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxidative Phosphorylation in Silent Pituitary Adenomas: A Multiomics Perspective.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the World Health Organization has clearly defined silent pituitary adenomas (SPAs) and functional adenomas (non-SPAs), the detailed biological mechanisms remain unclear. This study conducted a comprehensive analysis of clinical, genomic, transcriptomic, and proteomic differences between SPA and non-SPA. The results revealed significant differences in mutational profiles, with a notably higher mutation rate of the TCHH gene in non-SPA samples. Transcriptomic and proteomic analyses identified distinct expression patterns, highlighting the enrichment of the oxidative phosphorylation pathway and other related Gene Ontology terms in SPA samples. To validate these findings, 11 additional pituitary adenoma samples were analyzed, confirming the critical role of oxidative phosphorylation in SPA. Activation of oxidative phosphorylation altered the hormone secretion, and the electron transfer chain inhibitor restored this in both human and rat pituitary adenoma cell lines. Furthermore, a protein-protein interaction network was constructed, revealing key regulatory differences between SPA and non-SPA, and identifying MAPK1, MAPK3, IDH1, and PKM as key hubs in the network. MAPK1 and PKM knockdown significantly reduced the hormone secretion and apoptosis of both cell lines. These findings suggest that the oxidative phosphorylation pathway plays a pivotal role in the secretory functions of pituitary adenomas. This study offers new insights into the biological mechanisms underlying pituitary adenomas and provides valuable directions for future research, emphasizing the importance of oxidative phosphorylation in tumor behavior and potential therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.